• Aura Erazo Valle-Solís, Arturo Pabel Miranda-Aguirre, Josué Mora-Pérez, Juan Antonio Pineda-Juárez, Luis Ernesto Gallardo-Valencia, Liberio Santana, Guadalupe Cervantes-Sánchez, and Eduardo Cárdenas-Cárdenas.
• Neoplastic and Proliferative Disorders Division. Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, City of Mexico, Mexico.
• Gac Med Mex. 2019 Jan 1; 155 (Suppl 1): S39-S43.

BackgroundBreast cancer subtype classification according to hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) using immunohistochemistry is the standard practice for therapeutic decision making.ObjectiveTo design future studies information on characteristics and survival of each subtype is essential.MethodWe conducted a retrospective study to analyze clinical and pathologic features as well as survival data according to breast cancer immunohistochemistry subtype.ResultsThere were 211 women with a RH(+)/HER2(-) breast cancer subtype, 53 HR(+)/HER2(+), 16 HER2(+) and 23 HR(-)/HER2(-), with a median overall survival in months of 39 (20.5-62.7), 42 (25.5-65), 42 (13.7-67.7) and 26 (11-78), respectively, for a 3.7 hazard ratio of death (95% Confidence Interval [CI]: 1.3-10.3) for the triple negative group as compared to the HR(+)/HER2(-) group (p = 0.01).ConclusionsHR positive subtypes by immunohistochemistry where most frequent and showed a greater overall survival compared to the triple negative subtype.Copyright: © 2019 Permanyer.

19 keywords...

hide…